624 related articles for article (PubMed ID: 22845023)
1. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
[TBL] [Abstract][Full Text] [Related]
2. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
3. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.
Gelsomino S; Lorusso R; Romagnoli S; Bevilacqua S; De Cicco G; Billè G; Stefàno P; Gensini GF
Eur J Cardiothorac Surg; 2008 Jan; 33(1):64-71. PubMed ID: 17996457
[TBL] [Abstract][Full Text] [Related]
5. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
Bowman LJ; Uber WE; Stroud MR; Christiansen LR; Lazarchick J; Crumbley AJ; Kratz JM; Toole JM; Crawford FA; Ikonomidis JS
Ann Thorac Surg; 2008 May; 85(5):1669-76; discussion 1676-7. PubMed ID: 18442563
[TBL] [Abstract][Full Text] [Related]
6. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
Raivio P; Suojaranta-Ylinen R; Kuitunen AH
Ann Thorac Surg; 2005 Jul; 80(1):66-71. PubMed ID: 15975342
[TBL] [Abstract][Full Text] [Related]
7. Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation.
Hollis AL; Lowery AV; Pajoumand M; Pham SM; Slejko JF; Tanaka KA; Mazzeffi M
Ann Card Anaesth; 2016; 19(3):418-24. PubMed ID: 27397445
[TBL] [Abstract][Full Text] [Related]
8. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis.
Berkhof FF; Eikenboom JC
Transfusion; 2009 Mar; 49(3):570-7. PubMed ID: 19040498
[TBL] [Abstract][Full Text] [Related]
10. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.
Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH
Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247
[TBL] [Abstract][Full Text] [Related]
11. [The use of recombinant activated factor VII for blood loss after cardiovascular surgery].
Gong ZY; Gao CQ; Xiao CS; Li BJ; Ma XH; Zhang CM
Zhonghua Wai Ke Za Zhi; 2008 Oct; 46(19):1497-501. PubMed ID: 19094631
[TBL] [Abstract][Full Text] [Related]
12. Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.
Feih JT; Juul JJ; G Rinka JR; Baumann Kreuziger LM; Pagel PS; Tawil JN
Ann Card Anaesth; 2019; 22(4):388-393. PubMed ID: 31621674
[TBL] [Abstract][Full Text] [Related]
13. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
Pychyńska-Pokorska M; Pągowska-Klimek I; Krajewski W; Moll JJ
J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):987-94. PubMed ID: 21835642
[TBL] [Abstract][Full Text] [Related]
14. Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.
Tatoulis J; Theodore S; Meswani M; Wynne R; Hon-Yap C; Powar N
Interact Cardiovasc Thorac Surg; 2009 Sep; 9(3):459-62. PubMed ID: 19542087
[TBL] [Abstract][Full Text] [Related]
15. Recombinant activated factor VII in critical bleeding after orthotopic liver transplantation.
Busani S; Semeraro G; Cantaroni C; Masetti M; Marietta M; Girardis M
Transplant Proc; 2008; 40(6):1989-90. PubMed ID: 18675109
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.
von Heymann C; Redlich U; Jain U; Kastrup M; Schroeder T; Sander M; Grosse J; Ziemer S; Koscielny J; Konertz WF; Wernecke KD; Spies C
Crit Care Med; 2005 Oct; 33(10):2241-6. PubMed ID: 16215377
[TBL] [Abstract][Full Text] [Related]
17. Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass.
Guzzetta NA; Huch S; Fernandez JD; Tosone SR; Miller BE
Paediatr Anaesth; 2009 Apr; 19(4):364-70. PubMed ID: 19143947
[TBL] [Abstract][Full Text] [Related]
18. Use of recombinant activated factor VII (rFVIIa-NovoSeven) in the treatment of uncontrolled postsurgical hemorrhage in a patient with deep venous thrombosis and caval filter. A case report.
Marson F; Farnia A; Callegher L; Casagrande L; Surdu M; Sarpellon M
Minerva Anestesiol; 2006; 72(7-8):675-82. PubMed ID: 16865086
[TBL] [Abstract][Full Text] [Related]
19. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
Chapman AJ; Blount AL; Davis AT; Hooker RL
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
[TBL] [Abstract][Full Text] [Related]
20. Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience.
Karsies TJ; Nicol KK; Galantowicz ME; Stephens JA; Kerlin BA
Ann Thorac Surg; 2010 Feb; 89(2):570-6. PubMed ID: 20103344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
